Circulating levels of soluble receptor for advanced glycation end-products (sRAGE) have been suggested to have a protective role in neutralizing advanced glycation end-products (AGEs) and their pathological effects on vessel walls. We aimed to investigate the association between the circulating concentration of sRAGE and the dynamics of arterial wall stiffening as a manifestation of vascular aging in the general population. In a prospective cohort study, we longitudinally followed 530 general-population-based subjects (subsample of Czech post-MONICA study). Aortic pulse wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE were assessed at baseline by ELISA (R&D Systems). The average ∆PWV/year significantly decreased across the sRAGE quintiles (p = 0.048), and a drop by one sRAGE quintile was associated with an ~21% increase in the relative risk of accelerated age-dependent stiffening (∆PWV/year ≥ 0.2 m/s). Subjects in the bottom quintile of sRAGE (<889.74 pg/mL) had a fully adjusted odds ratio of accelerated stiffening of 1.72 (95% CI: 1.06-2.79), p = 0.028, while those with high sRAGE concentrations (≥1695.2 pg/mL) showed the opposite effect [odds ratio 0.55 (95% CI: 0.33-0.90), p = 0.017]. In conclusion, the circulating status of sRAGE independently influenced the individual progression of arterial stiffness over time. This finding strongly supports the hypothesis that high sRAGE has a protective role against vascular aging.

2nd Department of Internal Medicine Medical Faculty of Charles University and University Hospital Pilsen Czech Republic

Biomedical Center Medical Faculty of Charles University Pilsen Czech Republic

Centre for Cardiovascular Prevention of the 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department of Clinical Biochemistry and Hematology University Hospital Pilsen Czech Republic

Zobrazit více v PubMed

O’Rourke MF, Mancia G. Arterial stiffness. J Hypertens. 1999;17:1–4. PubMed

Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005;66:307–17. PubMed

Robert L. Aging of the vascular-wall and atherosclerosis. Exp Gerontol. 1999;34:491–501. PubMed

Folkow B, Svanborg A. Physiology of cardiovascular aging. Physiol Rev. 1993;73:725–64. PubMed

Collaboration TRVfAS. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010;31:2338–50.

Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54:1328–36. PubMed

McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005;46:1753–60. PubMed

Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597–605. PubMed

Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Investig. 1997;99:457–68. PubMed

Kalousova M, Zima T, Tesar V, Dusilova-Sulkova S, Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res. 2005;579:37–46. PubMed

Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196:9–21. PubMed

Georgianos PI, Pikilidou MI, Liakopoulos V, Balaskas EV, Zebekakis PE. Arterial stiffness in end-stage renal disease-pathogenesis, clinical epidemiology, and therapeutic potentials. Hypertens Res. 2018;41:309–19. PubMed

Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YCE, et al. Cloning and expression of a cell-surface receptor for advanced glycosylation end-products of proteins. J Biol Chem. 1992;267:14998–5004. PubMed

Schnider SL, Kohn RR. Effects of age and diabetes mellitus on the solubility and nonenzymatic glucosylation of human skin collagen. J Clin Investig. 1981;67:1630–5. PubMed

Vasan S, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 1996;382:275–8. PubMed

Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med. 2007;13:625–35. PubMed PMC

Park L, Raman KG, Lee KJ, Lu Y, Ferran JrLJ, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025. PubMed

Basta G, Corciu AI, Vianello A, Del Turco S, Foffa I, Navarra T, et al. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis. 2010;210:614–8. PubMed

Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:2587–93. PubMed

Mayer O, Seidlerova J, Filipovsky J, Vagovicova P, Wohlfahrt P, Cifkova R, et al. Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population. Hypertens Res. 2016;39:266–71. PubMed

Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032–7. PubMed

Cifkova R, Skodova Z, Bruthans J, Adamkova V, Jozifova M, Galovcova M, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis. 2010;211:676–81. PubMed

Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–605. PubMed

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207–74. PubMed

Herbert A, Cruickshank JK, Laurent S, Boutouyrie P. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur Heart J. 2014;35:3122–33. PubMed

Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35:2950–9. PubMed

Dimitriadis K, Tsioufis C, Kasiakogias A, Miliou A, Poulakis M, Kintis K, et al. Soluble receptor for advanced glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension. Nutr Metab Cardiovasc Dis. 2013;23:382–8. PubMed

Geroldi D, Falcone C, Emanuele E, D’Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23:1725–9. PubMed

McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens. 2007;20:242–7. PubMed

Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens. 2009;22:74–9. PubMed

Miranda ER, Somal VS, Mey JT, Blackburn BK, Wang E, Farabi S, et al. Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313:E631–e640. PubMed PMC

Yoon SJ, Park S, Park C, Chang W, Cho DK, Ko YG, et al. Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients. Coron Artery Dis. 2012;23:85–90. PubMed

Dozio E, Ambrogi F, de Cal M, Vianello E, Ronco C, Corsi Romanelli MM. Role of the soluble receptor for advanced glycation end products (sRAGE) as a prognostic factor for mortality in hemodialysis and peritoneal dialysis patients. Mediators Inflamm. 2018;2018:1347432. PubMed PMC

Jabaudon M, Blondonnet R, Pereira B, Cartin-Ceba R, Lichtenstern C, Mauri T, et al. Plasma sRAGE is independently associated with increased mortality in ARDS: a meta-analysis of individual patient data. Intensive Care Med. 2018;44:1388–99. PubMed PMC

Paradela-Dobarro B, Fernandez-Trasancos A, Bou-Teen D, Eiras S, Gonzalez-Ferreiro R, Agra RM, et al. Evolution and bad prognostic value of advanced glycation end products after acute heart failure: relation with body composition. Cardiovasc Diabetol. 2017;16:115. PubMed PMC

Rodriguez-Ruiz E, Lopez-Lago A, Hernandez-Vaquero R, Granja-Gomez I, Estany-Gestal A, Alvarez E, et al. First-days reduction of plasma and skin advanced glycation end products is related to outcome in septic patients. Shock. 2019. https://doi.org/10.1097/SHK.0000000000001396 [Epub ahead of print].

Grauen Larsen H, Yndigegn T, Marinkovic G, Grufman H, Mares R, Nilsson J, et al. The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event. Atherosclerosis. 2019;287:16–23. PubMed

Reichert S, Triebert U, Santos AN, Hofmann B, Schaller HG, Schlitt A, et al. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. Atherosclerosis. 2017;266:234–9. PubMed

Jensen LJ, Flyvbjerg A, Bjerre M. Soluble receptor for advanced glycation end product: a biomarker for acute coronary syndrome. Biomed Res Int. 2015;2015:815942. PubMed PMC

Grauen Larsen H, Marinkovic G, Nilsson PM, Nilsson J, Engstrom G, Melander O, et al. High plasma sRAGE (soluble receptor for advanced glycation end products) is associated with slower carotid intima-media thickness progression and lower risk for first-time coronary events and mortality. Arterioscler Thromb Vasc Biol. 2019;39:925–33. PubMed

Prasad K. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases? Mol Cell Biochem. 2019;451:139–44. PubMed

Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis. 2010;209:173–7. PubMed

Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005;16:2363–72. PubMed

Tan KCB, Chow WS, Tso AWK, Xu A, Tse HF, Hoo RLC, et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia. 2007;50:1819–25. PubMed

Tang SC, Wang YC, Li YI, Lin HC, Manzanero S, Hsieh YH, et al. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol. 2013;33:585–94. PubMed

Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Investig. 2003;111:959–72. PubMed

Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Investig. 1996;97:238–43. PubMed

Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464–70. PubMed

Oudegeest-Sander MH, Olde Rikkert MG, Smits P, Thijssen DH, van Dijk AP, Levine BD, et al. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial. Exp Gerontol. 2013;48:1509–17. PubMed PMC

Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens. 2004;17:23s–30s. PubMed

Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population?